Inactive Instrument

Surface Oncology, Inc. Stock price

Equities

SURF

US86877M2098

Biotechnology & Medical Research

Dynamic Chart
Surface Oncology, Inc.(NasdaqCM:SURF) dropped from S&P TMI Index CI
Surface Oncology, Inc.(NasdaqCM:SURF) dropped from S&P Global BMI Index CI
Coherus BioSciences Completes Acquisition of Surface Oncology MT
Surface Oncology, Inc. Announces Director Changes CI
Surface Oncology, Inc.(NasdaqCM:SURF) dropped from NASDAQ Composite Index CI
Coherus BioSciences, Inc. completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others. CI
Surface Oncology Says Takeover by Coherus BioSciences Gets Backing From ISS, Glass Lewis MT
Surface Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Surface Oncology, Inc.(NasdaqGM:SURF) dropped from Russell Microcap Index CI
Surface Oncology, Inc.(NasdaqGM:SURF) dropped from Russell Microcap Value Index CI
Surface Oncology, Inc.(NasdaqGM:SURF) dropped from Russell 3000E Index CI
Surface Oncology, Inc.(NasdaqGM:SURF) dropped from Russell 3000E Value Index CI
North American Morning Briefing : Investors Eye -2- DJ
Wedbush Downgrades Surface Oncology to Neutral From Outperform, Adjusts Price Target to $1.15 From $3 MT
Baird Downgrades Surface Oncology to Neutral From Outperform, Cuts Price Target to $1 From $6 MT
More news
Managers TitleAgeSince
Chief Executive Officer 50 16-09-30
Chief Tech/Sci/R&D Officer - 21-11-30
Corporate Officer/Principal - 16-10-31
Members of the board TitleAgeSince
Chief Executive Officer 50 16-09-30
More insiders
Surface Oncology, Inc. is a clinical-stage, immuno-oncology company, which is focused on developing immunotherapies that target the tumor microenvironment. The Company is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. The Company's pipeline includes two wholly owned clinical-stage programs targeting IL-27 (SRF388) and SRF114 a preclinical program focused on depleting tumor regulatory T cells through targeting CCR8. In addition, the Company has two partnerships with pharmaceutical companies, including a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562). The Company's novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.
More about the company
  1. Stock
  2. Equities
  3. Stock Surface Oncology, Inc. - Nasdaq